Abstract
With the availability of widespread SARS-CoV-2 vaccination, high-throughput quantitative anti-spike protein serological testing will likely become increasingly important. Here, we investigated the performance characteristics of the recently FDA-authorized semiquantitative anti-spike protein AdviseDx SARS-CoV-2 IgG II assay compared to the FDA-authorized anti-nucleocapsid protein Abbott Architect SARS-CoV-2 IgG, Roche Elecsys anti-SARS-CoV-2-S, EuroImmun anti-SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA), and GenScript surrogate virus neutralization assays and examined the humoral response associated with vaccination, natural protection, and vaccine breakthrough infection. The AdviseDx assay had a clinical sensitivity at 14 days after symptom onset or 10 days after PCR detection of 95.6% (65/68; 95% confidence interval [CI], 87.8 to 98.8%), with two discrepant individuals seroconverting shortly thereafter. The AdviseDx assay demonstrated 100% positive percent agreement with the four other assays examined using the same symptom onset or PCR detection cutoffs. Using a recently available WHO international standard for anti-SARS-CoV-2 antibody, we provide assay unit conversion factors to international units for each of the assays examined. We performed a longitudinal survey of healthy vaccinated individuals, finding that median AdviseDx immunoglobulin levels peaked 7 weeks after first vaccine dose at approximately 4,000 IU/ml. Intriguingly, among the five assays examined, there was no significant difference in antigen binding level or neutralizing activity between two seropositive patients protected against SARS-CoV-2 infection in a previously described fishing vessel outbreak and five health care workers who experienced vaccine breakthrough of SARS-CoV-2 infection, all with variants of concern. These findings suggest that protection against SARS-CoV-2 infection cannot currently be predicted exclusively using in vitro antibody assays against wild-type SARS-CoV-2 spike. Further work is required to establish protective correlates for SARS-CoV-2 infection.
Keywords: Abbott Architect; COVID-19; SARS-CoV-2; anti-SARS-CoV-2; coronavirus; correlates of protection; serology; spike IgG; spike protein; vaccination.
【저자키워드】 COVID-19, SARS-CoV-2, coronavirus, vaccination, serology, anti-SARS-CoV-2, Spike protein, correlates of protection, Abbott Architect, spike IgG, 【초록키워드】 Vaccine, vaccination, Health care, serology, SARS-COV-2 infection, variants of concern, in vitro, anti-SARS-CoV-2, variants, ELISA, Spike protein, Antigen, vaccine dose, Protein, enzyme-linked immunosorbent assay, Neutralizing activity, PCR, Humoral response, Characteristics, Immunoglobulin, Serological testing, anti-SARS-CoV-2 antibody, outbreak, International, Patient, Health care worker, WHO, Breakthrough infection, antibody assay, Roche, Euroimmun, Quantitative, seropositive, SARS-CoV-2 IgG, SARS-CoV-2 vaccination, Anti-spike, Protective, spike IgG, binding, international standard, clinical sensitivity, humoral, Abbott, can not, international units, symptom onset, Factor, antigen binding, fishing vessel, no significant difference, 95% confidence interval, enzyme, individual, wild-type SARS-CoV-2, Architect, vaccinated individuals, positive, Genscript, widespread, FIVE, vessel, enzyme-linked immunosorbent, described, predicted, performed, examined, healthy, investigated, peaked, required, median, demonstrated, increasingly, Elecsy, seroconverting, virus neutralization assay, 【제목키워드】 serologic, concordant, Level,